BioRem (CVE:BRM) Upgraded at Cormark

Cormark upgraded shares of BioRem (CVE:BRM) to a moderate buy rating in a report released on Tuesday morning,Zacks.com reports.

BioRem Stock Performance

CVE BRM opened at C$2.95 on Tuesday. The company has a debt-to-equity ratio of 48.97, a current ratio of 1.57 and a quick ratio of 1.08. BioRem has a 1 year low of C$0.95 and a 1 year high of C$3.39. The stock has a market capitalization of C$46.32 million, a PE ratio of 14.05 and a beta of 0.85. The company’s 50 day simple moving average is C$2.83 and its two-hundred day simple moving average is C$2.41.

Insider Activity

In related news, Director Derek Webb sold 120,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of C$2.93, for a total value of C$351,600.00. Insiders own 1.90% of the company’s stock.

BioRem Company Profile

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs.